MetaCap

Arrowhead Pharmaceuticals (ARWR) vs Liquidia (LQDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Liquidia (LQDA) has outperformed Arrowhead Pharmaceuticals (ARWR) over the past year, gaining 87.0% versus a gain of 2.3%. Over five years, LQDA leads with a +1224.3% price change compared with -42.6% for ARWR. Arrowhead Pharmaceuticals is the larger company by market cap ($5.85 billion vs $4.90 billion), about 1.2 times the size, while Liquidia is growing revenue faster (+1031.2% vs -45.6%).

Liquidia converts more of its revenue into profit, with a net margin of -43.5% versus -160.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARWR+2.27%LQDA+86.98%
+224%+101%-22%
Nov 21, 20251 yearNov 20, 2026
ARWR-41.82%LQDA+1177.70%
+2123%+966%-190%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARWR versus LQDA key metrics
MetricARWRLQDA
Share price$41.37$54.43
Market cap$5.85B$4.90B
1-day change-5.22%-3.88%
YTD return-37.69%+57.81%
1-year return+2.27%+86.98%
5-year return-42.56%+1224.33%
Forward P/E—15.12
EPS (TTM)$-5.11$-1.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$450.82M$158.32M
Revenue growth (YoY)-45.65%+1031.18%
Net income (latest FY)$-724.21M$-68.92M
Operating margin-156.86%-32.45%
Net margin-160.64%-43.53%
52-week high$95.49$93.61
52-week low$40.43$22.31
Distance from 52-week high-56.68%-41.85%
Analyst consensusstrong_buybuy
Avg. price target upside+156.39%+21.50%
Average volume2.08M3.52M
Shares outstanding141.37M90.11M
Employees1,062216
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LQDA has outperformed ARWR by 84.7 percentage points over the past year.
  • Liquidia is more profitable, keeping -43.5 cents of every revenue dollar as net income versus -160.6 cents for Arrowhead Pharmaceuticals.
  • Liquidia grew revenue faster in its latest fiscal year (+1031.18% vs -45.65%).

About Arrowhead Pharmaceuticals

ARWR stock →

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,062 employees

About Liquidia

LQDA stock →

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees

ARWR vs LQDA FAQ

Which is bigger, Arrowhead Pharmaceuticals or Liquidia?

Arrowhead Pharmaceuticals (ARWR) is larger, with a market capitalization of $5.85B compared with $4.90B for Liquidia (LQDA).

Which stock has performed better over the past year, ARWR or LQDA?

LQDA returned +86.98% over the past 12 months, compared with +2.27% for ARWR (price return, excluding dividends). Past performance does not predict future results.

Are Arrowhead Pharmaceuticals and Liquidia in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons